8-K
filed October 10, 2024, 7:59 PM ET
ticker IKT
CIK 0001750149
other material
confidence high
sentiment neutral
materiality 0.75
Inhibikase raises ~$110M in private placement; appoints four new directors
Inhibikase Therapeutics, Inc.
- Gross proceeds ~$110M from common stock, pre-funded warrants, and Series A-1/B-1 warrants at $1.37 per share unit.
- Company to seek stockholder approval to increase authorized shares; meeting within 90 days of close of offering.
- Board expands from 5 to 7; appoints Bellini, Munshi, Kush, Canner effective Oct 21.
- Series A-1 warrants ($1.37) expire 30 days after Phase 2b safety readout; Series B-1 ($1.49) after efficacy readout.
- New directors invest alongside: BSquared $2M, Munshi family $500K, Kush trust $200K, Soleus Capital ~$21.5M.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
David Canner was appointed as Class II Director at Inhibikase Therapeutics, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Amit Munshi and David Canner to serve as Class II directors of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Roberto Bellini was appointed as Class I Director at Inhibikase Therapeutics, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
the Board will appoint Roberto Bellini to serve as a Class I director of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Amit Munshi was appointed as Class II Director at Inhibikase Therapeutics, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Amit Munshi and David Canner to serve as Class II directors of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Arvind Kush was appointed as Class III Director at Inhibikase Therapeutics, Inc..
- Action
- appointed
- Role
- Class III Director
Exact text from the filing
Arvind Kush to serve as a Class III director of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Roberto Bellini was elected as Chairperson of the Board at Inhibikase Therapeutics, Inc..
- Action
- elected
- Role
- Chairperson of the Board
Exact text from the filing
It is expected that the Board will elect Mr. Bellini as Chairperson of the Board
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.